Lilly to participate in J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street rallies, Dow closes at record on Iran talks optimism
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Leerink on Eli Lilly (LLY): 'Orforglipron Delivers Weight Maintenance Following Injectables'
December 18, 2025 11:10 AM ESTLeerink Partners analyst David Risinger reiterated an Outperform rating and $1,104.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "We believe new maintenance data for LLYs oral once-daily GLP-1 candidate orforglipron will help drive commercial success and upside to consensus expectations. Our published orforglipron sales estimates vs. consensus are as follows: 2026E $2.0B vs. $1.4B, 2027E $9.0B vs. $3.3B, and 2028E $16.0B vs. $5.3B... More
